Analysis of ligands targeting other strong components of the SGLT2 network besides SGLT2 or SGLT1 revealed that ertugliflozin, sergliflozin etabonate, and dapagliflozin have additional targets associated with hypertension. This evidence concerns the gene SLC5A2 and Hypertension.